ClinConnect ClinConnect Logo
Search / Trial NCT06102070

Genetic Susceptibility to Severe Infections

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Oct 20, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating why some people develop severe infections while others do not, despite being exposed to the same germs. Researchers believe that both our genetics (what we inherit from our parents) and our environment play a role in how our immune system responds to infections. By studying individuals with rare and severe infections, the goal is to better understand these diseases, which could lead to new treatments and improved care for patients.

To participate in this trial, individuals must have a confirmed rare and severe infection and be receiving treatment in a specialized hospital, such as in the emergency room or intensive care unit. They also need to be connected to the French Social Security system. Family members of affected individuals may also be eligible to participate. Importantly, those who have certain acquired immune deficiencies, like those who have received immunosuppressive treatments recently or are HIV positive, cannot participate. If you join the study, you will help researchers learn more about these infections and potentially contribute to finding better ways to treat them.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • to sign the informed consent signed by the patient. In the case of a minor patient, consent is signed by the holders of parental authority. In the case of a protected adult patient, the consent is signed by their legal representative. In the case of an adult patient unable to consent at the time of inclusion, consent is signed by a family member.
  • to have a proven rare and severe infection
  • to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care
  • to be affiliated to the French Social Security system
  • for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces
  • Exclusion Criteria
  • to have an acquired immunodeficiency (having received immunosuppressive treatment in the 3 months preceding the onset of the disease or being HIV positive)
  • pregnant woman at the time of illness

About Institut National De La Santé Et De La Recherche Médicale, France

The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.

Locations

Paris, Ile De France, France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported